The Side Effects and Adverse Clinical Cases Reported after COVID-19 Immunization

Vaccines, Journal Year: 2022, Volume and Issue: 10(4), P. 488 - 488

Published: March 22, 2022

COVID-19 remains a deadly disease that poses serious threat to humanity. vaccines protect the public and limit viral spread. However, acceptance is significantly dependent on efficacy side effects (SEs) of vaccinations being produced. Four important mechanisms have been examined for vaccines: DNA-based, mRNA-based, protein-based, inactivated viruses. Vaccination safety research was formerly limited manufacturer-sponsored studies, but numerous additional cross-sectional survey-based studies conducted globally contributed generation vaccine-related data reports. Twenty-seven twenty-four case reports published-up till 2021 were overviewed presentation SEs their severity. Injection site pain remained most dominant localized SE, while headache fatigue prevalent systemic SEs. Most reported all safe, with very little or no adverse effects, nature be more persistent in DNA- mRNA-based vaccines, associated longer-duration Overall, found women youngsters. Case reactions also documented, there still need find out pathological linkage vaccination.

Language: Английский

---

COVID-19, Vaccines, and Thrombotic Events: A Narrative Review

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(4), P. 948 - 948

Published: Feb. 11, 2022

The coronavirus disease 2019 (COVID-19), a deadly pandemic that has affected millions of people worldwide, is associated with cardiovascular complications, including venous and arterial thromboembolic events. Viral spike proteins, in fact, may promote the release prothrombotic inflammatory mediators. Vaccines, coding for protein, are primary means preventing COVID-19. However, some unexpected thrombotic events at unusual sites, most frequently located cerebral sinus but also splanchnic, thrombocytopenia, have emerged subjects who received adenovirus-based vaccines, especially fertile women. This clinical entity was soon recognized as new syndrome, named vaccine-induced immune probably caused by cross-reacting anti-platelet factor-4 antibodies activating platelets. For this reason, regulatory agencies various countries restricted use vaccines to age groups. prevailing opinion experts, however, risk developing COVID-19, clearly outweighs potential risk. point-of-view aims providing narrative review epidemiological issues, data, pathogenetic hypotheses thrombosis linked both COVID-19 its helping medical practitioners offer up-to-date evidence-based counseling their often-alarmed patients acute or chronic

Language: Английский

---

Global reports of takotsubo (stress) cardiomyopathy following COVID-19 vaccination: A systematic review and meta-analysis

IJC Heart & Vasculature, Journal Year: 2022, Volume and Issue: 43, P. 101108 - 101108

Published: Aug. 17, 2022

Concerns have been raised recently about takotsubo cardiomyopathy (TCM) after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines. The goal of this study was to compile case reports provide a comprehensive overview associated with A systematic literature search conducted in PubMed, Scopus, Embase, Web Science, and Google Scholar between 2020 June 1, 2022. included individuals who developed cardiac from vaccinations. Ten studies, including 10 cases, participated current review. mean age 61.8 years; 90 % were female, while male. 80 patients received mRNA vaccine, 20 other types. In addition, occurred 50 first dose another 40 second Moreover, number days onset symptoms 2.62 days. All cases had an elevated troponin test abnormal ECG findings. left ventricular ejection fraction (LVEF) lower than patients. terms average length hospital stay, stayed for 10.2 days, all recovered their symptoms. conclusion, (stress) complications vaccination are rare but can be life-threatening. Chest pain should considered alarming symptom, especially those doses vaccine.

Language: Английский

---

Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 424 - 424

Published: April 17, 2025

Vaccination has been instrumental in curbing the transmission of SARS-CoV-2 and mitigating severity clinical manifestations associated with COVID-19. Numerous COVID-19 vaccines have developed to this effect, including BioNTech-Pfizer Moderna’s mRNA vaccines, as well adenovirus vector-based such Oxford–AstraZeneca. However, emergence new variants subvariants SARS-CoV-2, characterized by enhanced transmissibility immune evasion, poses significant challenges efficacy current vaccination strategies. In review, we aim comprehensively outline landscape emerging concern (VOCs) sub-lineages that recently surfaced post-pandemic years. We assess effectiveness existing their booster doses, against these subvariants, BA.2-derived sub-lineages, XBB BA.2.86 (Pirola). Furthermore, discuss latest advancements vaccine technology, multivalent pan-coronavirus approaches, along development several next-generation coronavirus exosome-based, virus-like particle (VLP), mucosal, nanomaterial-based vaccines. Finally, highlight key critical areas for future research address evolving threat develop strategies combating viral threats, thereby improving preparedness pandemics.

Language: Английский

---

The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia

Clinical Medicine, Journal Year: 2022, Volume and Issue: 22(2), P. 140 - 144

Published: March 1, 2022

ABSTRACT

In the new science emanating from COVID-19 pandemic, effective vaccine development has made a huge difference and saved countless lives. Vaccine roll-out led to identification of rare cases severe thrombotic thrombocytopenic problems in some recipients. This apparent coupling thrombosis with haemorrhagic potentiation might seem baffling but ensuing clinical investigation rapidly shed important light on its molecular mechanism. review outlines current understanding role adenovirus-based platforms, immunogenic triggers immunothrombotic response underlying vaccine-induced immune thrombocytopenia.

Language: Английский

---

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation

Frontiers in Pain Research, Journal Year: 2022, Volume and Issue: 3

Published: Nov. 8, 2022

This study aimed to assess the prevalence and clinical characteristics of headaches, in particular secondary headaches.This observational was performed at ASST Spedali Civili Brescia, Italy. Visits Emergency Department (ED) subsequent hospitalizations regarding a new or worsening headache 16 days following administration COVID-19 vaccine between January 2021 2022 were recorded compared with those 2019-January 2020.The ratio ED admissions due headaches total significantly higher 2019 (4.84% vs. 4.27%; p < 0.0001). Two-hundred eighty-nine (10.8% all admissions) time-correlated vaccination, which 40 hospitalized order exclude symptomatic etiology. At discharge, 32 patients had diagnosis benign not attributed any cranial/extracranial disorder eight headache, whose diagnoses following: Headache cranial and/or cervical vascular (n = 4); nonvascular intracranial 2); facial pain cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, other structure 1); painful lesions nerves 1). The most frequently reported by migraine-like characteristics: localization predominantly frontal temporal, described as throbbing severe intensity it accompanied nausea/vomit, photo-phonophobia. Over half-regardless final diagnosis-of history primary headaches.Following spread number increased. However, less than 14% visits vaccination actually hospitalized, documenting possibly related generic side effects vaccination. Only 8/40 diagnosed headache. These would fulfill diagnostic criteria for 8.1 Headaches use exposure substance (ICHD-3), although, time being, does include vaccines possible substances.The characteristics' could suggest activation trigeminovascular pathway cytokines pro-inflammatory molecules released

Language: Английский

---

Global reports of takotsubo (stress) cardiomyopathy following COVID-19 vaccination: a systematic review and meta-analysis

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: April 19, 2022

Abstract Concerns have been raised recently about takotsubo cardiomyopathy (TCM) after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines. The goal of this study was to compile case reports provide a comprehensive overview associated with A systematic literature search conducted in PubMed, Scopus, Embase, Web Science, and Google Scholar between 2020 June 1, 2022. included individuals who developed cardiac from vaccinations. Ten studies, including 10 cases, participated current review. mean age 61.8 years; 90% were female, while 10% male. 80% patients received mRNA vaccine, 20% other types. In addition, occurred 50% first dose another 40% second Moreover, number days onset symptoms 2.62 days. All cases had an elevated troponin test abnormal ECG findings. left ventricular ejection fraction (LVEF) lower than patients. terms average length hospital stay, stayed for 10.2 days, all recovered their symptoms. conclusion, (stress) complications vaccination are rare but can be life-threatening. Chest pain should considered alarming symptom, especially those doses vaccine.

Language: Английский

---

COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine

OALib, Journal Year: 2022, Volume and Issue: 09(04), P. 1 - 20

Published: Jan. 1, 2022

Since the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in December 2019, it has spread rapidly affecting numerous people globally and World Health Organization (WHO) declared a pandemic March 2020.As cases COVID-19 continue to rise daily, there are increasing concerns controversies regarding best methods curb pandemic.Since no proven drugs that completely effective for prevention or treatment SARS-CoV-2, vaccines considered be most favorable choice control this disease reduce morbidity mortality from COVID-19.Therefore, evidence-based intensive literature review aims further identify thoroughly understand mechanisms actions primary developed against aiming provide latest information available on current vaccines, touching viral characteristics vaccine development platforms which may beneficial advancing research novel SARS-CoV-2 vaccines.

Language: Английский

---

Case Report: A Case of COVID Vaccine-Induced Thrombotic Thrombocytopenia Manifested as Pulmonary Embolism and Hemorrhagia. A First Reported Case From Slovakia

Frontiers in Medicine, Journal Year: 2022, Volume and Issue: 8

Published: Jan. 4, 2022

COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) is a rare complication of adenoviral vector (ChAdOx1 nCoV-19) vaccine administration. It presented as and manifestations in various sites, especially cerebral veins. Pulmonary emboli have been reported rarely. We present case young male patient who developed severe pulmonary embolism 12 days after the first dose vaccine. Severe thrombocytopenia, skin hematomas, segmental were detected. Anti-platelet factor 4 (aPF-4) antibody was highly positive supporting diagnosis VITT. Prompt treatment with fondaparinux, intravenous immunoglobulin, prednisone led to marked improvement clinical condition thrombocytes count. report known VITT Slovakia.

Language: Английский

---

Editorial for the Special Issue “Emergency Medicine and Emergency Room Medical Issues”

Medicina, Journal Year: 2023, Volume and Issue: 59(2), P. 380 - 380

Published: Feb. 16, 2023

Together with the "law of entropy", two main reasons for risk burnout among physicians who work in emergency departments around world are variety clinical issues presented by patients and absence guidelines managing most them [...].

Language: Английский

---